Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients

Bibliography

• Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Payne D, Jacobson P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81:129-34
   PubMed Web of Science ®Google Scholar
• Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Oncol Hematol 2011;80:460-5
   PubMed Web of Science ®Google Scholar
• Zeppetella GB. Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage 2008;35:563-7
   PubMed Web of Science ®Google Scholar
• Ashburn M, Streisand J. Oral trasmucosal fentanyl. Help or hindrance? Drug Saf 1994;11:295-300
   PubMed Web of Science ®Google Scholar
• Csaba N, Garcia-Fuentes M, Alonso MJ. The performance of nanocarriers for transmucosal drug delively. Expert Opin Drug Deliv 2006;91:463-78
   Google Scholar
• Streisand J, Varvel J, Stanski DR, Absorption and availability of moral trasmucosal fentanyl citrate. Anesthesiology 1991;75:223-9
   PubMed Web of Science ®Google Scholar
• Aronoff G, Brennan M, Pritchard D, Ginsberg B. Evidence-based pral transmucosal fentanyl citrate (OTFC) dosing guidelines. Pain Med 2005;6:305-14
   PubMed Web of Science ®Google Scholar
• Streisand JB, Busch MA, Egan TD, Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology 1998;88:305-9
   PubMed Web of Science ®Google Scholar
• Lee M, Kern S, Kisicki J, Egan T. A pharmacokinetic study to compare two simultaneous 400 microg doses with a single 800 microg dose of oral transmucosal fentanyl citrate. J Pain Symptom Manage 2003;26:743-7
   PubMed Web of Science ®Google Scholar
• Egan T, Sharma A, Ashburn M, Multiple dose pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers. Anesthesiology 2000;92:665-73
   PubMed Web of Science ®Google Scholar
• Kharasch E, Whittington D, Hoffer C. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucisal fenatnyl citrate. Anesthesiology 2004;101:729-37
   PubMed Web of Science ®Google Scholar
• Shaiova L, Lapin J, Manco L, Tolerability and effects of two formulations of oral trasmucosal fentanyl citrate (OTFC;ACTIQ) in patients with radiation-induced oral mucositis. Support Care Cancer 2004;12:268-73
   PubMed Web of Science ®Google Scholar
• Davies A, Vriens J. Oral trasnsmucosal fentanyl citrate and xerostomia. J Pain Symptom Manage 2005;30:496-7
   PubMed Web of Science ®Google Scholar
• Farrar J, Cleary J, Rauck R, Oral transmucosal fentanyl citrate: a randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998;90:611-16
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Payne R, Coluzzi P, Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999;79:303-12
   PubMed Web of Science ®Google Scholar
• Christie J, Simmonds M, Patt R, Dose-titration multicenter study of transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998;16:3238-45
   PubMed Web of Science ®Google Scholar
• Coluzzi P, Schwartzberg L, Conroy J, Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulphate immediate release (MSIR). Pain 2001;91:123-30
   PubMed Web of Science ®Google Scholar
• Mercadante S, Villari P, Ferrera P, Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer 2007;96:1828-33
   PubMed Web of Science ®Google Scholar
• Mercadante S, Radbruck L, Davies A, A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomized, crossover trial. Curr Med Res Opin 2009;25:2805-15
   PubMed Web of Science ®Google Scholar
• Davies AN, Dickman A, Reid C, Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009;13:331-8
   PubMed Web of Science ®Google Scholar
• Hagen NA, Fisher K, Victorino C, Farrar JT. A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. J Palliat Med 2007;10:47-55
   PubMed Web of Science ®Google Scholar
• Hanks GW, Nugent M, Higgs C, Busch M. Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer; an open, multicentre, dose-titration and long-term use study. Palliat Med 2004;18:698-704
   PubMed Web of Science ®Google Scholar
• Burton AW, Driver L, Mendoza T, Syed G. Oral transmucosal citrate in the outpatient management of severe cancer pain crisis: a retrospective case series. Clin J Pain 2004;20:195-7
   PubMed Web of Science ®Google Scholar
• Payne R, Coluzzi P, Hart L, Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage 2001;22:575-83
   PubMed Web of Science ®Google Scholar
• Mandel L, Carunchio MJ. Rampant caries from oral transmucosal fentanyl citrate lozenge abuse. J Am Dent Assoc 2011;142:405-9
   Web of Science ®Google Scholar
• Mercadante S. Fentanyl buccal tablet in breakthrough pain in opioid-tolerant patients with cancer: a viewpoint by Sebastiano Mercadante. Drugs 2006;66:2394-5
   Google Scholar